دورية أكاديمية
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer
| العنوان: | Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer |
|---|---|
| المؤلفون: | Garzon S, Grassi T, Mariani A, Kollikonda S, Weaver AL, McGree ME, Petersen IA, Weroha SJ, Glaser GE, Langstraat CL, Amarnath SR, AlHilli MM |
| المساهمون: | Garzon, S, Grassi, T, Mariani, A, Kollikonda, S, Weaver, Al, Mcgree, Me, Petersen, Ia, Weroha, Sj, Glaser, Ge, Langstraat, Cl, Amarnath, Sr, Alhilli, Mm |
| سنة النشر: | 2022 |
| المجموعة: | Università degli Studi di Verona: Catalogo dei Prodotti della Ricerca (IRIS) |
| مصطلحات موضوعية: | Adjuvant therapy, Early-stage, Endometrial cancer, High-intermediate risk, High-risk, Oncologic outcomes |
| الوصف: | ObjectiveTo evaluate recurrence-free survival (RFS) and cause-specific survival (CSS) after observation or vaginal brachytherapy (VB) alone in all subgroups of early-stage high-intermediate (HIR) and high-risk endometrial cancer (EC).MethodsWe identified patients with stage I HIR (GOG-249 criteria) and stage II endometrioid EC, and stage I and II non-endometrioid EC who underwent surgery at Mayo Clinic and Cleveland Clinic between 1999 and 2016. Three-year RFS and CSS after observation or VB only were estimated in 16 subgroups defined by risk factors.ResultsAmong 4156 ECs, we identified 447 (10.8%) stage I endometrioid HIR, 52 (1.3%) stage II endometrioid, 350 (8.4%) stage I non-endometrioid, and 17 (0.4%) stage II non-endometrioid ECs; observation or VB alone was applied in 349 (78.1%), 24 (46.2%), 187 (53.4%), and 2 (11.8%) patients, respectively. After observation or VB, stage I HIR endometrioid EC subgroups with <2 factors among grade 3, LVSI, or stage IB had a 3-year CSS >95% (lower 95% confidence intervals limit: 89.8%), whereas subgroups with ≥2 factors had poorer outcomes. No EC-related deaths after 3 years were reported in 97 stage IA non-endometrioid ECs without myometrial invasion. Stage II ECs had poor outcomes regardless of histology.ConclusionsObservation or VB only may be sufficient in stage I endometrioid HIR ECs with <2 factors among grade 3, LVSI, or IB and in stage IA non-endometrioid ECs without myometrial invasion. Stratification of early-stage HIR and high-risk ECs into risk subgroups potentially alleviates the overtreatment and undertreatment risk and should be considered in future research. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36244826; info:eu-repo/semantics/altIdentifier/wos/WOS:000929697400008; volume:167; issue:3; firstpage:444; lastpage:451; numberofpages:8; journal:GYNECOLOGIC ONCOLOGY; https://hdl.handle.net/11562/1080268Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85139843047 |
| DOI: | 10.1016/j.ygyno.2022.10.004 |
| الإتاحة: | https://doi.org/10.1016/j.ygyno.2022.10.004Test https://hdl.handle.net/11562/1080268Test |
| رقم الانضمام: | edsbas.5F42E29B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ygyno.2022.10.004 |
|---|